Craig Crews

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Vivace Therapeutics, Inc. discovers and develops novel cancer drug. The company was founded by Shuang Qiao in 2014 and is headquartered in San Mateo, CA.

Canaan Management, Inc. (Canaan Management) is a venture capital firm founded in 1987 by Eric A. Young. The firm is headquartered in Westport, CT.

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY.

Part of Canaan Management, Inc., Canaan Partners XI LLC provides investment services. The company is based in Wilmington, DE.

CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA.

Rallybio LLC operates as a development-stage biotechnology company. The firm develops transformative therapies for patients. It focuses on bringing life-transforming medicines to patients with devastating and rare disorder. The company was founded by Martin Mackay, Stephen Uden and Jeffrey Fryer in 2018 and is headquartered in Farmington, CT.

Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT.

Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA.

Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021.

Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments.

Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA.

Oxeon Investments LLC (Oxeon Investments) is a venture capital firm founded in 2011 by Trevor Price. The firm is headquartered in New York with additional offices in Seattle, Washington and Nashville, Tennessee.